Treatment with fixed-dos combination sofosbuvir/velpatasvir yielded significant improvements in patient-reported outcomes.
The oral disease-modifying drug under development for the treatment of relapsing-remitting multiple sclerosis, teriflunomide, was not superior to interferon beta-1a in risk of treatment failure.